Search

Ionis Pharmaceuticals Inc

Abierto

SectorSanidad

63.58 4.43

Resumen

Variación precio

24h

Actual

Mínimo

59.32

Máximo

61.66

Métricas clave

By Trading Economics

Ingresos

-22M

-115M

Ventas

22M

268M

BPA

-0.7

Margen de beneficios

-42.787

Empleados

1,480

EBITDA

-37M

-105M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+48.43% upside

Dividendos

By Acuity

Próximas Ganancias

28 oct 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

495M

9.7B

Apertura anterior

59.15

Cierre anterior

63.58

Noticias sobre sentimiento de mercado

By Acuity

60%

40%

287 / 340 Clasificación en Healthcare

Ionis Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

22 ago 2026, 00:01 UTC

Ionis Pharmaceuticals Inc is higher in after-market trading, reflecting strength amid a broader market rebound. The stock remains above its 20-day moving average.

21 ago 2026, 22:51 UTC

Ionis Pharmaceuticals Inc shares are trading higher during after-market hours, remaining above the 20-day moving average and near the upper end of their one-month range.

20 ago 2026, 20:02 UTC

News
Event

Ionis Pharmaceuticals will present new data on hypertriglyceridemia treatments at the European Society of Cardiology Congress, though shares are trading lower today.

19 ago 2026, 23:06 UTC

News

Ionis Pharmaceuticals is advancing RG-6299 into a pivotal Phase III trial for IgA nephropathy in collaboration with Roche and Chugai. Shares are higher in after-market trading.

18 ago 2026, 20:06 UTC

Ionis Pharmaceuticals Inc shares are higher, supported by strong momentum above the 20-day moving average. No specific news was identified for today's move.

17 ago 2026, 23:01 UTC

Ionis Pharmaceuticals Inc shares are lower in after-market hours, reflecting a decline since Monday's close amid broader market weakness and geopolitical tensions.

14 ago 2026, 22:02 UTC

Ionis Pharmaceuticals shares are higher in after-market trading. No specific news was identified to explain the movement amid broader economic concerns.

13 ago 2026, 19:56 UTC

Ionis Pharmaceuticals Inc shares are lower today, reflecting broader market trends. First-time unemployment claims rose, but overall investor sentiment remains stable.

12 ago 2026, 23:56 UTC

Ionis Pharmaceuticals Inc. shares are lower in after-market trading, despite remaining above their 20-day moving average and within the upper range for the month.

11 ago 2026, 23:46 UTC

Ionis Pharmaceuticals shares are higher in after-market trading, reaching a high near the upper end of their one-month range. No specific news was identified.

10 ago 2026, 21:01 UTC

Ionis Pharmaceuticals Inc shares are lower in after-market hours. Broader market sentiment is cautious following weaker-than-expected labor market data.

7 ago 2026, 20:03 UTC

News

Ionis Pharmaceuticals shares are higher today amid increased market volume. HC Wainwright revised Q3 2026 loss estimates, maintaining a "Buy" rating.

6 ago 2026, 20:03 UTC

Macro Event

Ionis Pharmaceuticals Inc shares are higher, supported by high trading volume, though they remain below their 20-day moving average and near a one-month low.

5 ago 2026, 23:56 UTC

Ionis Pharmaceuticals shares are lower in after-market hours, influenced by a disappointing ADP employment report revealing only 44,000 private sector jobs added in July.

4 ago 2026, 23:41 UTC

Ionis Pharmaceuticals Inc shares are lower in after-market hours, having reached a session low earlier. No specific news was identified to explain the movement.

3 ago 2026, 20:51 UTC

Ionis Pharmaceuticals Inc. shares are trading roughly flat in after-market hours, maintaining a cumulative return of 0.02% since Monday's close.

1 ago 2026, 00:06 UTC

Ionis Pharmaceuticals Inc shares are higher in after-market hours, recovering from recent declines amid broader market gains, including a rise in the Nikkei 225 Index.

31 jul 2026, 23:01 UTC

Ionis Pharmaceuticals Inc shares are higher in after-market hours, supported by a notable advance in the Biotechnology sub-sector. No specific news was identified.

30 jul 2026, 23:46 UTC

Ionis Pharmaceuticals shares are slightly higher in after-market hours, though no specific news explains the movement amid mixed Asian equity performance and geopolitical concerns.

29 jul 2026, 23:51 UTC

Ionis Pharmaceuticals Inc is trading lower in after-market hours, continuing a trend of four consecutive sessions below its 20-day moving average.

28 jul 2026, 18:03 UTC

News

Ionis Pharmaceuticals shares are lower amid an investigation by Bronstein, Gewirtz & Grossman and disappointing earnings forecasts projecting a loss of $1.07 per share.

27 jul 2026, 20:07 UTC

News
Social Media

Ionis Pharmaceuticals shares are lower amid an investigation into potential claims following the company's disclosure about its failed Phase-3 trial.

25 jul 2026, 00:02 UTC

Ionis Pharmaceuticals Inc shares are lower in after-market hours, diverging from recent gains. No specific news was identified to explain the decline.

24 jul 2026, 21:01 UTC

Ionis Pharmaceuticals Inc shares are lower in after-market hours, following a broader market decline driven by disappointing earnings from major companies and falling crude oil prices.

23 jul 2026, 20:03 UTC

Ionis Pharmaceuticals Inc shares are higher during Thursday's session, continuing a notable increase since Wednesday. Trading volume is unusually high today.

22 jul 2026, 22:26 UTC

Ionis Pharmaceuticals shares are slightly higher in after-market hours. Broader market conditions reflect ongoing geopolitical tensions and rising crude oil prices.

21 jul 2026, 21:01 UTC

Ionis Pharmaceuticals Inc shares are lower in after-market hours, with no specific news identified to explain the decline. The broader market is rebounding.

20 jul 2026, 23:01 UTC

Ionis Pharmaceuticals Inc shares are higher in after-market trading, recovering from earlier lows after three consecutive daily declines. No specific news was identified.

Comparación entre iguales

Cambio de precio

Ionis Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

48.43% repunte

Estimación a 12 Meses

Media 88.67 USD  48.43%

Máximo 115 USD

Mínimo 60 USD

De acuerdo con 20 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ionis Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

20 ratings

16

Comprar

4

Mantener

0

Vender

Sentimiento

By Acuity

287 / 340 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura bajista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.